Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Sep 9 - Sep 14
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Our brand personality is rooted in empathy, innovation, trustworthiness, support, results-orientation, and personalization
However, specific policies and support mechanisms vary across different NHS trusts and Integrated Care Boards (ICBs)
Frontiers in Pharmacology, 14 , 1267765
WHY APEX
US$ 20.59
US$ 29.80
US$ 28.38
US$ 25.10
